CASP1 and alkaline phosphatase measurement: Genetic ablation or pharmacologic inhibition of pyroptosis successfully eliminated the detrimental effects caused by AP treatments, opening a promising avenue for cell death-based treatment of diseases, especially because VX-765, the Casp1 inhibitor used in this study,32 is currently undergoing a phase II clinical evaluation.